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assessed on Day 15 during induction, and its prognostic value was analyzed in 1,431 patients treated on
ALL-BFM 95. RESULTS: The 8-year probabilities of event-free survival were 86.1%, 74.5%, and 46.4%
for patients with M1, M2, and M3 Day 15 marrows, respectively. Compared to prednisone response,
Day 15 marrow response was superior in outcome prediction in precursor B-cell and T-cell leukemia
with, however, a differential effect depending on blast lineage. Outcome was poor in T-cell leukemia
patients with prednisone poor-response independent of Day 15 marrow response, whereas among patients
with prednisone good-response different risk groups could be identified by Day 15 marrow response. In
contrast, prednisone response lost prognostic significance in precursor B-cell leukemia when stratified
by Day 15 marrow response. Age and white blood cell count retained their independent prognostic
effect. CONCLUSIONS: Selective addition of Day 15 marrow response to conventional stratification
criteria applied on ALL-BFM 95 (currently in use in several countries as regular chemotherapy protocol
for childhood acute lymphoblastic leukemia) may significantly improve risk-adapted treatment delivery.
Even though cutting-edge trial risk stratification is meanwhile dominated by minimal residual disease
evaluation, an improved conventional risk assessment, as presented here, could be of great importance
to countries that lack the technical and/or financial resources associated with the application of minimal
residual disease analysis.
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 Prediction of Outcome by Early Response in Childhood 
Acute Lymphoblastic Leukemia
 Das frühe Ansprechen auf die Therapie als prognostischer Faktor bei der 
akuten lymphoblastischen Leukämie im Kindesalter
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 Abstract
 ▼
 Background:  In the ALL-BFM studies for treat-
ment of acute lymphoblastic leukemia, reduction 
of leukemic blasts in peripheral blood after a 
one-week prednisone pre-phase – the so-called 
prednisone response – has been used for risk 
stratifi cation since the 1980s and has been one of 
the most relevant factors for identifi cation of 
high-risk patients. In the trial ALL-BFM 95, early 
cytomorphological marrow response on day 15 
of induction therapy was prospectively evaluated 
and its prognostic value was analyzed in com-
parison to the prednisone response and other 
established prognostic factors.
 Results:  Compared to prednisone response, day 
15 marrow response was superior in outcome 
prediction – yet with diﬀ erential eﬀ ect depend-
ing on blast lineage. Outcome was poor in T cell 
leukemia patients with prednisone poor-
response independent of day 15 marrow 
response, whereas among patients with pred-
nisone good-response diﬀ erent risk groups could 
be identifi ed by day 15 marrow response. In con-
trast, prednisone response lost prognostic signif-
icance in precursor B cell leukemia when 
stratifi ed by day 15 marrow response.
 Conclusions:  Selective addition of day 15 mar-
row response to conventional stratifi cation crite-
ria applied on ALL-BFM 95 may signifi cantly 
improve risk-adapted treatment delivery. Even 
though cutting-edge trial risk stratifi cation is 
meanwhile dominated by minimal residual dis-
ease evaluation, an improved conventional risk 
assessment, as presented here, could be of great 
importance to countries lacking the technical 
and/or fi nancial resources associated with the 
application of minimal residual disease analysis.
 Zusammenfassung
 ▼
 Hintergrund:  Die Blastenreduktion im peri-
pheren Blut nach einer einwöchigen Prednison-
Vorphase – der sogenannte Prednison-Response 
– wird in den ALL-BFM-Studien zur Behandlung 
von Kindern mit akuter lymphoblastischer 
Leukämie seit den 1980er Jahren für die Risikos-
tratifi zierung herangezogen und stellt einen der 
wichtigsten Faktoren für die Identifi zierung von 
Hochrisikopatienten dar. In der Studie ALL-BFM 
95 wurde zusätzlich das frühe zytomorpholo-
gische Ansprechen auf die Therapie am Tag 15 
der Induktionstherapie im Knochenmark pro-
spektiv untersucht und dessen prognostischer 
Wert im Vergleich zum Prednison-Response und 
anderen etablierten Prognosefaktoren analysiert.
 Ergebnisse:  Das zytomorphologische Ansprechen 
im Knochenmark am Tag 15 war als prognos-
tischer Faktor dem Prednison-Response insge-
samt überlegen, jedoch mit unterschiedlichem 
Eﬀ ekt in Abhängigkeit vom Immunphänotyp der 
Blasten. Während bei Patienten mit B-Vor-
läuferzell-Leukämie der Prednison-Reponse in 
Kombination mit dem Ansprechen am Tag 15 
seine prognostische Wertigkeit komplett verlor, 
war bei Patienten mit T-Zell-Leukämie ein 
 schlechter Prednison-Response auch bei gutem 
Ansprechen am Tag 15 prognostisch ungünstig.
 Schlussfolgerung:  Die Verwendung des zyto-
morphologischen Therapieansprechens am Tag 
15 in der Induktionstherapie für die Risikostra-
tifi zierung kann im Vergleich zur konventionel-
len Stratifi zierung der Studie ALL-BFM 95 eine 
bessere Risikoadaptierung der Therapie ermögli-
chen. Auch wenn mittlerweile in vielen aktuellen 
Therapiestudien die zytomorphologische Evalua-
tion des Therapieansprechens weitgehend durch 
Methoden zur Erfassung der minimalen Rester-
krankung abgelöst wurde, kann insbesondere in 
Ländern, in denen keine ausreichenden Mittel 
Aﬃ  liations Aﬃ  liation addresses are listed at the end of the article
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were used for stratifi cation into 3 risk groups: (i) High Risk (HR: 
PPR, and/or no CR on day 33, and/or evidence of t(9;22) [or BCR/
ABL], and/or evidence of t(4;11) [or MLL/AF4]), (ii) Medium Risk 
(MR: No HR criteria, and initial WBC  ≥ 20 000/μl, and/or age at 
diagnosis  < 1 or  ≥ 6 years, and/or T-ALL), or (iii) Standard Risk 
(SR: No HR criteria, and initial WBC < 20 000/μl, and age at diag-
nosis  ≥ 1 and  < 6 years, and no T-ALL).
 Bone marrow on day 15 (BMd15) was prospectively assessed 
without being used for risk stratifi cation. From the 2 169 patients 
enrolled, 1 431 patients had assessable information on BM 
 morphology on day 15  [ 17 ] and were included in the study on 
cytomorphological treatment response presented here. The esti-
mated probability of 8-year EFS (8y-pEFS) of these patients was 
78.8 ± 0.9 %. The data reported here shall focus on the additional 
value of BMd15 compared with the so far used PR and BM 
response on day 33 (BMd33).
 Prognostic value of prednisone response and marrow 
response on day 15 and day 33
 ▼
 PR was evaluable in 1 419 of the 1 431 analyzed patients (99 %) 
refl ecting the very easy sampling and evaluation of the periph-
eral blood samples on day 8. In contrast, 15.6 % of the BM aspi-
rates on day 15 were considered not assessable due to 
non-representative BM morphology. Stratifi cation by PR resulted 
in 1 280 patients with PGR (90.2 %) and 139 patients with PPR 
(9.8 %). Using BMd15, 880 patients (61.5 %) had an M1, 365 
patients (25.5 %) an M2 and 186 patients (13.0 %) an M3 marrow.
 The prediction of treatment outcome was in principal possible 
with both response parameters PR or BMd15. The 8y-pEFS was 
81.3 ± 0.9 % for patients with PGR and 55.1 ± 3.7 % for patients 
with PPR (p < 0.001). For the patients with M1, M2 and M3 mar-
row, 8y-pEFS was 86.1 ± 1.2 %, 74.5 ± 2.3 %, and 46.4 ± 3.7 %, 
respectively. In view of the fact that the group with the worst 
outcome identifi ed by BMd15 (M3) is slightly larger and has a 
somewhat worse pEFS than PPR patients, one can suspect that 
BMd15 allows a better prediction of outcome than PR consider-
ing the total patient population. In addition, BMd15 allowed the 
further stratifi cation of the large “good risk” patient group (M1, 
M2). However, applying these generally used cut-oﬀ  values 
characterizing M1, M2 and M3 marrow, each subgroup still com-
prises patients with a wide range of BM blasts. Analyzing the 
patients within narrower ranges of blasts resulted in a clear dif-
ference in pEFS between 0 % and  > 0 % to  < 5 % (M1 category) and 
between 25 % to  < 50 % and  ≥ 50 % BM blasts on day 15 (M3 cat-
egory) (  ●  ▶   Fig. 1 ).
 Poor response in BMd15 was signifi cantly associated with 
T-ALL ( p < 0.001) and the known high-risk features adolescent 
age ( p < 0.001), hyperleukocytosis ( p < 0.001), BCR/ABL ( p = 0.003), 
CNS involvement ( p = 0.005), PPR ( p < 0.001), and NRd33 
( p < 0.001).
 BMd33 could be assessed in 1 415 of 1 431 patients. Only 42 of 
these patients (2.9 %) did not achieve BM remission on day 33 
(NRd33). Although these patients had a strikingly poor 8y-pEFS 
of only 36.3 ± 6.9 %, cytomorphological marrow response at this 
time point has limited prognostic value for the vast majority of 
für Analysen der minimalen Resterkrankung  verfügbar sind, 
eine verbesserte konventionelle Risikoeinschätzung entschei-
dend zur Qualität der Therapie beitragen.
 Introduction
 ▼
 Early treatment response is known to be of major importance for 
the prediction of outcome in solid and hematologic malignan-
cies  [ 6 ,  14 ,  15 ,  18 ] . In 1983, the Berlin-Frankfurt-Münster (BFM) 
study group started to evaluate the so-called prednisone 
response (PR) as a predictive factor for treatment outcome by 
measuring the peripheral blast count after a 7-day therapy of 
prednisone and one intrathecal (IT) dose of methotrexate (MTX) 
 [ 28 ] . Since then, the PR has consistently been found to be one of 
the strongest independent prognostic factors for the prediction 
of treatment outcome in ALL-BFM studies  [ 24 ] .
 In the 1970s the Children’s Cancer Study Group (CCG) evaluated 
early bone marrow response during multi-agent induction 
treatment and demonstrated its predictive value for achieve-
ment of remission and ultimate outcome  [ 11 ,  21 ,  22 ] . In the fol-
lowing trials, the CCG generated many data on the prognostic 
importance of marrow response on day 7 and 14, the combined 
impact of the 2 evaluation points, and the diﬀ erential eﬀ ect in 
patients at standard or high risk by the NCI/Rome criteria 
 [ 9 ,  12 ,  32 ,  36 ] . Based on these results, early marrow response has 
become an integral part of risk stratifi cation in the succeeding 
CCG and contemporary Children’s Oncology Group (COG) ALL 
treatment regimens  [ 2 ,  16 ,  19 ,  20 ,  25 ,  33 ] . The St. Jude Total Ther-
apy Study Group showed that even the persistence of low per-
centages (1–4 %) of BM lymphoblasts on day 15 (corresponding 
to day 22 of the BFM protocol without prednisone prephase) and 
days 22–25 of induction therapy was associated with a signifi -
cantly poorer event free survival rate compared to patients 
without detectable BM blasts  [ 29 ] .
 Here we will summarize the importance of cytomorphological 
response in bone marrow and peripheral blood at diﬀ erent 
investigation time points during induction treatment within an 
ALL-BFM treatment regimen. In the trial ALL-BFM 95  [ 23 ] , the 
prognostic value of cytomorphological response in BM on day 15 
(BMd15) was evaluated in comparison and combined with the 
clinical and treatment response parameters established in the 
ALL-BFM 95 risk stratifi cation such as PR, cytomorphological BM 
response to induction therapy (day 33), age and white blood cell 
count (WBC) at diagnosis.
 Response evaluation and risk stratifi cation in trial 
ALL-BFM 95
 ▼
 Evaluation of treatment response was an integral part of risk 
stratifi cation in ALL-BFM 95. PR was evaluated by the determi-
nation the absolute number of leukemic blasts/μl in the periph-
eral blood after 7 days of prednisone treatment and one 
intrathecal (IT) dose of methotrexate, regardless of the initial 
leukemic blast count. Prednisone good responders (PGR) were 
characterized by  < 1 000 blasts/μl, whereas prednisone poor 
responders (PPR) had  ≥ 1 000 blasts/μl on day 8 of treatment 
 [ 28 ] . Response in BM was categorized as M1 ( < 5 %), M2 (5 
to  < 25 %), and M3 ( ≥ 25 % lymphoblasts) and was evaluated for 
risk assignement at the end of induction treatment (day 33). In 
addition to response criteria, clinical and biological parameters 
D
ow
nl
oa
de
d 
by
: H
au
pt
bi
bl
io
th
ek
 U
ni
ve
rs
itä
t Z
ür
ich
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
S52 Zum 80. Geburtstag von Prof. Riehm
 Möricke A et al. Prediction of Outcome by … Klin Padiatr 2013; 225 (Suppl. 1): S50–S56 
patients. However, using BMd33 in addition to BMd15 enables a 
further stratifi cation of patients with M3 BMd15. Among these 
patients 8y-pEFS was 52.5 ± 4.2 % (n = 146) for those who 
achieved complete cytomorphological remission (CR) by day 33 
and 25.4 ± 7.2 % (n = 38) for those, who did not (p < 0.001).
 In clinical practice, the question often arises whether an early 
change or intensifi cation of treatment is reasonable in patients 
with very poor early response. Of the patients with  ≥ 75 % blasts 
on day 15, 55 % reached CR on day 33 and had an 8y-pEFS of 
42.9 ± 12.6 %. Among those patients with 25 to  < 50 % blasts on 
day 15, even 92 % reached CR on day 33 with an 8y-pEFS of 
57.5 ± 5.5 %. These data show that patients with M3 marrow on 
day 15 still have a good chance to achieve CR by end of induction. 
This suggests that just for the aim of achieving remission there is 
no strong evidence for the need of alternative ALL treatment at 
this point. However, treatment results of these patients are still 
poor and might be improved by early treatment intensifi cation.
 Results in immunological subgroups
 ▼
 More detailed analyses revealed profound diﬀ erences within 
immunophenotypic subgroups. For this reason, results are 
shown for each subgroup separately.
 pB-ALL
 In pB-ALL (n = 1 196 [1187 patients with evaluable PR]), patients 
with PGR had an 8y-pEFS of 80.2 ± 1.2 % (n = 1 109) and PPR 
patients an 8y-pEFS of 58.4 ± 5.6 % (n = 78) ( p < 0.001). Patients of 
the BMd15 subgroups had an 8y-pEFS of 86.5 ± 1.3 % (n = 741), 
74.2 ± 2.5 % (n = 317), and 47.1 ± 4.3 % (n = 138) for the M1, M2 and 
M3 group. Compared with the total patient group, it is even 
more obvious in this immunological subgroup that the BMd15 
has a better prognostic discriminative value in identifying poor 
risk patients than the PR: A smaller group of pB-ALL patients 
could be identifi ed by PPR compared to M3 BMd15 (6.6 % vs. 
11.5 %), but the EFS of the patients in the M3 BMd15 group was 
even worse than the EFS of PPR patients. This was also refl ected 
in the distribution of events: 12.7 % of all events in pB-ALL 
(n = 32/256) clustered in the PPR group, whereas 28.5 % were 
detected in the BMd15 M3 group (n = 72/256) (  ●  ▶   Fig. 2a, b ). Sen-
sitivity of PR to predict poor BM response on day 15 or day 33 
was low as only 27.9 % of patients with M3 BMd15 and 56.7 % of 
patients with NRd33 had shown PPR before.
 BMd15 allowed a clear separation of 3 diﬀ erent risk groups for 
patients with M1, M2 and M3 marrow within the subgroups of 
PGR and PPR patients (  ●  ▶   Fig. 2a, b ). Patients of the same BMd15 
subgroup had no statistically signifi cant diﬀ erence in pEFS, 
when analyzed according to PR (  ●  ▶   Table 1 ).
 Age and WBC as well as NCI risk criteria  [ 34 ,  35 ] and risk group 
criteria of the trial ALL-BFM 95 – both using age at diagnosis and 
initial WBC – showed an additional prognostic value when ana-
lyzed in combination with BMd15 (  ●  ▶   Table 1 ).
 Multivariate Cox regression analysis including NCI risk criteria, 
PR, BMd15 and BMd33 as covariates confi rmed the univariate 
results. In this analysis, PR lost its prognostic signifi cance (PPR: 
RR 0.92, p = 0.72) whereas the NCI risk criteria (NCI HR: RR 2.17, 
p < 0.001) as well as BM response on day 15 (M2: RR 1.96, 
p < 0.001; M3: RR 3.93, p < 0.001) and day 33 (no CRd33: RR 2.14, 
p = 0.006) retained signifi cance.
 To summarize, BMd15 could identify 3 distinct risk groups in 
pB-ALL and PR had no signifi cant additional eﬀ ect in patients 
stratifi ed by BMd15. Biologically, this seems highly plausible 
considering that the PR is measured after the administration of 
7 days of prednisone and one IT dose of MTX, while the evalua-
tion of the BM on d15 refl ects the response to 14 days of pred-
nisone, one dose of vincristine, daunorubicin and asparaginase, 
respectively, and 2 doses of IT MTX. This additionally might indi-
cate that in pB-ALL, resistance to prednisone can be compen-
sated by high sensitivity to other chemotherapeutic drugs and 
that high sensitivity to prednisone can be overturned by resist-
ance to other agents.
 T-ALL
 In T-ALL (n = 194 [191 patients with evaluable PR]), PGR patients 
had an 8y-pEFS of 84.6 ± 3.3 % (n = 130) and patients with PPR 
had an 8y-pEFS of 54.1 ± 6.4 % (n = 61). The 8y-pEFS of patients 
with M1, M2 and M3 BMd15 was 86.9 ± 3.3 % (n = 107), 78.8 ± 6.7 % 
(n = 40), and 45.0 ± 7.7 % (n = 47). Sensitivity of PR to predict poor 
BM response on day 15 or day 33 was better in T-ALL than in pB-
ALL: 72.3 % of the patients with M3 BMd15 and 81.8 % of the 
patients with NRd33 had shown PPR before.
 Within the patients with PPR, BMd15 was not able to character-
ize subgroups with signifi cantly diﬀ erent outcome (  ●  ▶   Fig. 2d ). 
In PGR, however, outcome of patients with BMd15 M3 was sig-
nifi cantly worse (M3, 8y-pEFS 43.1 ± 14.7 %) compared with the 
M1 and M2 subgroup with similarly favourable results (M1: 
8y-pEFS 91.1 ± 3.0 %, M2: 8y-pEFS 83.4 ± 7.7 %,   ●  ▶   Fig. 2c ). The 
prognostic relevance of the PR within the BMd15 subgroups in 
T-ALL is illustrated by the reverse analysis in   ●  ▶   Table 1 : Within 
the BMd15 M1 subgroup, patients with signifi cantly worse pEFS 
could be identifi ed through PPR, whereas no diﬀ erence in out-
come was shown within the BMd15 M3 subgroup. Within the 
small BMd15 M2 subgroup, the diﬀ erence between PGR and PPR 
did not reach statistical signifi cance. Thus, by the combination of 
PR and BMd15, T-ALL patients can be stratifi ed into 2 distinct 
risk groups, one of them including the patients with PGR plus 
M1 or M2 BMd15 (n = 120, 8y-pEFS = 89.5 ± 2.9 %) the other 
M3 75% to 100% n=29,    19 events: 8y-pEFS 37.6%, SE=9.1%
M3 50% to <75% n=61,    36 events: 8y-pEFS 39.9%, SE=6.4%
M3 25% to <50% n=96,    45 events: 8y-pEFS 53.1%, SE=5.2%
M2 5% to <25% n=365,  95 events: 8y-pEFS 74.5%, SE=2.3%
M1 >0% to <5% n=664,105 events: 8y-pEFS 83.8%, SE=1.5%
M1 0% n=216,  15 events: 8y-pEFS 93.0%, SE=1.7%
pE
FS
years
13121110987654321
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
 Fig. 1  Kaplan-Meier estimate of event-free survival according to 
percentage of blast counts in the bone marrow on day 15  [ 17 ] . Log-Rank 
test (pair-wise comparisons): M1 (0 %) vs. M1 ( > 0 ≤ 5 %)  p = 0.001; M3 
(25 ≤ 50 %) vs. M3 (50 ≤ 75 %)  p = 0.102; M3 (25 ≤ 50 %) vs. M3 (75–100 %) 
 p = 0.025; M3 (50 ≤ 75 %) vs. M3 (75–100 %)  p = 0.381. 8y-pEFS indicates 
probability of event-free survival at 8 years; SE, standard error. 
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lyzed in a multivariate model including the MRD risk groups. In 
pB-ALL in contrast, PPR completely lost its adverse prognostic 
value if compared with PGR patients with the same PCR-MRD 
levels  [ 4 ] .
 Implication for risk stratifi cation in current and future 
ALL trials
 For more than 20 years, cytomorphological response has been 
the leading criterion for stratifying patients into risk groups 
within the ALL-BFM trials. Since ALL-BFM 86, cytomorphologi-
cal response has been estimated very early during induction 
treatment using the PR as criterion for risk stratifi cation. Cyto-
morphological treatment response in the BM, however, was 
evaluated only at the end of induction treatment (day 33). Poor 
cytomorphological response at either response evaluation point 
qualifi ed a patient for high-risk treatment  [ 5 ,  24 ,  27 ] .
 The prognostic signifi cance of early reduction of leukemic blasts 
in BM at diﬀ erent points during induction treatment was shown 
in a number of pediatric ALL trials (for review see Gaynon et al. 
 [ 12 ] ) and was implemented as risk stratifi cation criterion in 
various international trials  [ 1 ,  3 ,  8 ,  10 ,  26 ,  32 ,  36 ,  38 ] . Specifi city 
of response evaluation might, nevertheless, vary depending on 
including all patients with PPR and/or M3 BMd15 (n = 74, 
8y-pEFS 52.1 ± 5.9 %;  p < 0.001) (  ●  ▶   Fig. 3 ).
 NCI risk criteria had a borderline signifi cant prognostic value in 
patients with M1 BMd15, but showed no statistic signifi cance in 
patients with M2 or M3 BMd15 (  ●  ▶   Table 1 ).
 Consistent with these results, multivariate Cox regression analy-
sis including NCI risk criteria, PR, BMd15 and BMd33 as covari-
ates revealed BMd15 M3 as the strongest independent adverse 
risk factor (RR 2.93, p = 0.008 and in addition marginal signifi -
cance for PPR (RR 1.99, p = 0.059) and NCI-HR (RR 2.25, p = 0.092).
 The biological considerations which might explain the minor 
prognostic importance of PR compared with BMd15, seem to be 
less applicable for T-ALL patients. The data indicate that resist-
ance to prednisone (i. e., PPR) in T-ALL eventually could not be 
overcome by the following chemotherapy even in those patients, 
who apparently had a reasonable response in the later course of 
induction treatment as refl ected by M1 or M2 BMd15. The reli-
ability of these data might be weakened due to the small patient 
numbers remaining in the T-ALL subgroups in this analysis. 
However, the results are supported by the recently published 
data on the prognostic impact of MRD in the AIEOP-BFM ALL 
2000 trial  [ 31 ] . In this study, the PR in T-ALL also retained a – 
though just borderline signifi cant – prognostic value when ana-
years
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0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13
M1 d15    n=90, 8 events:   8y-pEFS 91.1%, SE=3.0%
M2 d15    n=27, 4 events:   8y-pEFS 83.4%, SE=7.7%
M3 d15    n=13, 7 events:   8y-pEFS 43.1%, SE=14.7%
P^
years
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13
M1 d15   n=14,   6 events: 8y-pEFS 57.1%, SE=13.2%
M2 d15   n=13,   4 events: 8y-pEFS 69.2%, SE=12.8%
M3 d15   n=34, 18 events: 8y-pEFS 47.1%, SE=8.6%
P^
a b
c d
 Fig. 2  Kaplan-Meier estimate of event-free survival according to bone marrow response on day 15 stratifi ed by immunophenotypic lineage and prednisone 
response  [ 17 ] . For defi nition of bone marrow M1, M2, and M3 see the Design and Methods section.  a pB-ALL, prednisone good-response; Log-Rank test (pair-
wise comparisons): all  p values  < 0.001.  b pB-ALL, prednisone poor-response; Log-Rank test: M1 vs. M2  p = 0.042; M2 vs. M3  p = 0.007; M1 vs. M3  p = 0.002; 
 c T-ALL, prednisone good-response; Log-Rank test: M1 vs. M2  p = 0.44; M2 vs. M3  p = 0.005; M1 vs. M3  p < 0.001;  d T-ALL, prednisone poor-response; Log-Rank 
test: M1 vs. M2  p = 0.65; M2 vs. M3  p = 0.22; M1 vs. M3  p = 0.42. 8y-pEFS indicates probability of event-free survival at 8 years; SE, standard error. 
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fi cation parameter. However, in ALL-BFM 95 the good outcome 
of pB-ALL patients with PPR and subsequently good BM response 
on day 15 was achieved with an intensifi ed high-risk treatment. 
Whether these results could be reproduced with less intensive 
treatment, remains unclear. This should be carefully considered 
before omitting the PR as a risk stratifi cation parameter in these 
patients.
 While in pB-ALL the combination of PR with BMd15 failed to 
improve risk group separation obtained through by BMd15 
alone, the use of the ALL-BFM 95 or the NCI risk criteria, both 
using age and initial WBC, in addition to BMd15 gave an added 
prognostic value. In the COG (or formerly CCG) protocols, the 
the time of response evaluation with regard to the therapy and 
the composition of the treatment  [ 30 ,  36 ,  37 ] .
 In view of the prognostic impact of PR and BMd15 in ALL-BFM 
95, one should scrutinize if the PR is still needed for risk stratifi -
cation when using BMd15. In the stratifi cation of T-ALL patients, 
it is obvious that combining BMd15 with PR added signifi cant 
value to BMd15 alone and allowed the stratifi cation into 2 
widely separated risk groups, the better of them with an excel-
lent 8y-pEFS of almost 90 % and another poor risk group with an 
8y-pEFS near 50 % including 74 % of all T-ALL events. For patients 
with pB-ALL, in contrast, the data on early treatment reponse in 
ALL-BFM 95 may suggest that the PR could be omitted as strati-
 Table 1  Treatment outcome in pB-ALL and T-ALL by age and WBC at diagnosis, diﬀ erent risk group classifi cations and treatment response  [ 17 ] . 
  Bone marrow day 15 
  M1  M2  M3 
 Variable  N ( %)  8y-pEFS,  
% (SE) 
 p 1  N ( %)  8y-pEFS,  
% (SE) 
 p 1  N ( %)  8y-pEFS, 
 % (SE) 
 p 1 
 pB-ALL          
 Age (years)         
   < 1 5  8 (1.1)  62.5 (17.1)   10 (3.2)  20.0 (12.6)   6 (4.3)  16.7 (15.2)  
   1 ≤ 10  312 (82.6)  88.8 (1.3)  < 0.001 4  253 (79.8)  81.8 (2.5)  < 0.001 4  89 (64.5)  51.3 (5.3)  0.133 4 
   ≥ 10  121 (16.3)  75.7 (4.3)   54 (17.0)  46.3 (7.9)   43 (31.2)  43.6 (7.7)  
 Initial WBC (× 10 9 /L)         
   < 50  648 (87.4)  88.2 (1.3)  < 0.001  262 (82.6)  75.7 (2.7)  0.160  92 (66.7)  53.7 (5.3)  0.015 
   ≥ 50  93 (12.6)  74.8 (4.5)   55 (17.4)  67.2 (6.3)   46 (33.3)  33.9 (7.1)  
 Risk group (ALL-BFM 95) 2         
   standard  327 (44.1)  91.8 (1.5)  < 0.001  109 (34.4)  84.8 (3.5)  < 0.001  17 (12.3)  70.6 (11.1)  0.002 
   intermediate  384 (51.8)  83.7 (1.9)   162 (51.1)  72.4 (3.6)   63 (45.7)  52.9 (6.4)  
   high  30 (4.0)  66.7 (8.6)   46 (14.5)  55.9 (7.4)   58 (42.0)  33.9 (6.3)  
 NCI/Rome risk group 3         
   standard  537 (73.3)  90.6 (1.3)  < 0.001  213 (69.4)  81.7 (2.7)  < 0.001  59 (44.7)  58.8 (6.5)  0.016 
   high  196 (26.7)  76.0 (3.2)   94 (30.6)  62.8 (5.2)   73 (55.3)  40.7 (5.8)  
 Prednisone response         
   good  725 (98.5)  86.4 (1.3)  0.20  286 (90.8)  74.7 (2.6)  0.51  98 (72.1)  51.1 (5.1)  0.088 
   poor  11 (1.5)  100 (0.0)   29 (9.2)  68.0 (8.8)   38 (27.9)  39.5 (7.9)  
 Remission day 33         
   no  0 (0.0)  –  –  3 (1.0)  –  –  28 (20.6)  23.6 (8.2)  < 0.001 
   yes  733 (100)  86.8 (1.3)   310 (99.0)  74.3 (2.5)   108 (79.4)  54.0 (4.8)  
 T-ALL          
 Age (years)          
   < 1 5  0 (0.0)  –   1 (2.5)  –   0 (0.0)  –  
   1 ≤ 10  67 (62.6)  88.1 (4.0)  0.65  26 (65.0)  80.6 (7.8)  0.76  24 (51.1)  56.8 (10.5)  0.126 
   ≥ 10  40 (37.4)  85.0 (5.6)   13 (32.5)  67.7 (17.1)   23 (48.9)  34.2 (10.0)  
 Initial WBC (×10 9 /L)         
   < 50  55 (51.4)  92.7 (3.5)  0.069  18 (45.0)  75.7 (10.7)  0.89  17 (36.2)  20.2 (15.5)  0.46 
   ≥ 50  52 (48.6)  80.7 (5.5)   22 (55.0)  81.8 (8.2)   30 (63.8)  53.3 (9.1)  
 Risk group (ALL-BFM 95) 2         
   standard  –  –   –  –   –  –  
   intermediate  93 (86.9)  91.4 (2.9)  < 0.001  27 (67.5)  83.4 (7.7)  0.168  11 (23.4)  50.9 (16.3)  0.26 
   High  14 (13.1)  57.1 (13.2)   13 (32.5)  69.2 (12.8)   36 (76.6)  44.4 (8.3)  
 NCI/Rome risk group 3         
   standard  32 (29.9)  96.6 (3.1)  0.054  12 (30.8)  82.5 (11.3)  0.62  6 (12.8)  41.7 (30.4)  0.26 
   high  75 (70.1)  82.6 (4.4)   27 (69.2)  76.0 (8.7)   41 (87.2)  43.8 (7.8)  
 Prednisone response         
   good  90 (86.5)  91.1 (3.0)  < 0.001  27 (67.5)  83.4 (7.7)  0.168  13 (27.7)  43.1 (14.7)  0.58 
   poor  14 (13.5)  57.1 (13.2)   13 (32.5)  69.2 (12.8)   34 (72.3)  47.1 (8.6)  
 Remission day 33          
   no  –  –  –  1 (2.6)  –  –  10 (21.3)  30.0 (14.5)  0.129 
   yes  106 (100)  86.8 (3.3)   38 (97.4)  80.3 (6.8)   37 (78.7)  49.3 (8.7)  
 1  The p value (log-rank test) refers to comparison within BMd15 subgroups;  2   Risk groups according to the risk criteria of trial ALL-BFM 95;  3  NCI/Rome standard risk, age 1 year 
or older and less than 10 years and WBC less than 50 000/μl; NCI/Rome high risk, age 10 years or older or WBC 50 000/μl or higher; Infants less than 1 year were excluded from 
the NCI defi nition;  4  The p value (log-rank test) refers to comparison of the age groups 1 to less than 10 years vs. 10 years and older;  5   Patients treated in the Interfant-99 pilot 
study were excluded 
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combination of NCI risk criteria with early (day 7 and day 14) 
marrow response has been used for risk stratifi cation for many 
years  [ 13 ,  32 ] . The ALL IC-BFM study group introduced cytomor-
phological BM response on day 15 in the non-MRD-based proto-
col ALL IC-BFM 2002 for a risk stratifi cation system which was 
based on the ALL-BFM 95 criteria, but shifted the patients to a 
higher risk group in the case of an M3 BMd15  [ 7 ] . ALL IC-BFM 
2002 was performed in countries, which did not have access to 
MRD diagnostics, mainly due to fi nancial burden  [ 7 ] . For these 
countries, optimization of risk stratifi cation by the intelligent 
use of clinical parameters and cytomorphological response eval-
uation is worthwhile. However, the prognostic relevance of cyto-
morphological response has always to be interpreted in the 
context of the specifi c chemotherapy regimen administered. 
Thus, transferring the treatment response data of ALL-BFM 95 
onto other – in particular less intensive – treatment regimens 
has to be done with caution.
 The ALL-BFM 95 protocol is currently used as regular chemo-
therapy protocol for childhood ALL in several countries. Our data 
demonstrate that the inclusion of BM response on day 15 cru-
cially improves the ALL-BFM 95 risk stratifi cation in the context 
of the ALL-BFM 95 therapy which is of particular interest in less 
aﬄ  uent countries in which expensive laboratory techniques are 
not aﬀ ordable. 
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